141 related articles for article (PubMed ID: 20601660)
1. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.
Pece A; Isola V; Piermarocchi S; Calori G
Br J Ophthalmol; 2011 Jan; 95(1):56-68. PubMed ID: 20601660
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.
Campochiaro PA; Hafiz G; Channa R; Shah SM; Nguyen QD; Ying H; Do DV; Zimmer-Galler I; Solomon SD; Sung JU; Syed B
Ophthalmology; 2010 Dec; 117(12):2387-2394.e1-5. PubMed ID: 20630595
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
5. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
Brown DM; Campochiaro PA; Bhisitkul RB; Ho AC; Gray S; Saroj N; Adamis AP; Rubio RG; Murahashi WY
Ophthalmology; 2011 Aug; 118(8):1594-602. PubMed ID: 21684606
[TBL] [Abstract][Full Text] [Related]
6. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.
Charbel Issa P; Finger RP; Kruse K; Baumüller S; Scholl HP; Holz FG
Am J Ophthalmol; 2011 May; 151(5):876-886.e1. PubMed ID: 21334595
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
Holz FG; Amoaku W; Donate J; Guymer RH; Kellner U; Schlingemann RO; Weichselberger A; Staurenghi G;
Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
[TBL] [Abstract][Full Text] [Related]
8. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
9. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.
Sacu S; Pemp B; Weigert G; Matt G; Garhofer G; Pruente C; Schmetterer L; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3046-50. PubMed ID: 21051706
[TBL] [Abstract][Full Text] [Related]
10. Adult-onset vitelliform detachment unresponsive to monthly intravitreal ranibizumab.
Kandula S; Zweifel S; Freund KB
Ophthalmic Surg Lasers Imaging; 2010; 41 Suppl():S81-4. PubMed ID: 21117608
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.
Heier JS; Brown D; Ciulla T; Abraham P; Bankert JM; Chong S; Daniel PE; Kim IK
Ophthalmology; 2011 Jan; 118(1):111-8. PubMed ID: 20678799
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
13. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.
Arias L; Caminal JM; Badia MB; Rubio MJ; Catala J; Pujol O
Retina; 2010; 30(10):1601-8. PubMed ID: 21060271
[TBL] [Abstract][Full Text] [Related]
15. Retinal artery occlusion following intravitreal anti-VEGF therapy.
von Hanno T; Kinge B; Fossen K
Acta Ophthalmol; 2010 Mar; 88(2):263-6. PubMed ID: 19416108
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for retinal vein occlusion.
Shimura M; Yasuda K; Nakazawa T; Takeshita T; Shiono T; Sakamoto T
Ophthalmology; 2010 Sep; 117(9):1858, 1858.e1-3. PubMed ID: 20816249
[No Abstract] [Full Text] [Related]
17. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for refractory uveitis-related macular edema.
Acharya NR; Hong KC; Lee SM
Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
